Kim-Trang Ho
Interventional Cardiology · Houston, TXNPI 1194222356
Payments from drug & device makers
Across 195 payments — averaging $75.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Boston Scientific$2K
- Medtronic$2K
- Edwards Lifesciences$2K
- Sanofi-aventis U.S. LLC$290
- Pfizer$277
- plus $1K from 18 others
What the payments were for
- Grants$2,00014%
- Travel & lodging$5,09135%
- Food & beverage$7,59952%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 74 | $6,061 |
| Boston Scientific | 25 | $2,499 |
| Medtronic | 5 | $2,259 |
| Edwards Lifesciences | 26 | $1,849 |
| Sanofi-aventis U.S. LLC | 8 | $290 |
| Pfizer | 13 | $277 |
| Abiomed | 2 | $202 |
| Actelion Pharmaceuticals US, Inc. | 6 | $195 |
| Teleflex LLC | 1 | $168 |
| AstraZeneca | 7 | $134 |
| Cardiovascular Systems Inc. | 1 | $126 |
| Shockwave Medical, Inc | 4 | $122 |
| Bridgebio Pharma, Inc. | 3 | $98 |
| Amgen | 5 | $85 |
| Merck | 4 | $83 |
| Novartis | 2 | $57 |
| Boehringer Ingelheim | 2 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $33 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Contego Medical, Inc | 1 | $19 |
| Chiesi USA, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUPERA$2,187
- OPTIS$1,108
- SAPIEN 3 Ultra RESILIA$483
- GALLANT$282
- JETSTREAM SC$177
- TURNPIKE$168
- COREVALVE EVOLUT R$167
- iLab Ultrasound Imaging System$137
- AVEIR$130
- Emerge Push$128
- Diamondback Peripheral$126
- Diamondback Coronary$126
- WOLVERINE CORONARY CUTTING BALLOON$125
- ESPRIT$123
- PERCLOSE PROGLIDE$117
- Perclose ProStyle$115
- Impella$110
- SAMURAI$105
- JETI$103
How this compares
$14,691 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 28 | $19,071 |
| ClopidogrelClopidogrel Bisulfate | 43 | $1,318 |
| Minocycline Hcl | 11 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $134 | $19,07128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Abhijeet DhobleHouston$2.7M
- John IsaacHouston$1.8M
- Amir KashaniHouston$1.3M
- Biswajit KarHouston$785K
- Michele SartoriHouston$603K
- Guilherme SilvaHouston$516K
- Sachin KumarHouston$446K
- Marwan JumeanHouston$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.